Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business

Josh Sullivan

Generate Life Sciences is the largest private newborn stem cell biorepository, and with the announcement of its own in-house manufacturing facility, the company is looking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business

Josh Sullivan

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL

Al­ready sit­ting on a ma­jor stem cell bank, Gen­er­ate looks to grow its re­gen­er­a­tive med­i­cines busi­ness

Josh Sullivan

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Already sitting on a major stem cell bank, Generate looks to grow its regenerative medicines business

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Applied Therapeutics' rare disease drug gets a CRL